奥沙利铂联合化疗方案与顺铂联合化疗方案治疗老年晚期非小细胞肺癌的对比研究

目的对比奥沙利铂(L-OHP)加吉西他滨(GEM)方案与顺铂(DDP)加吉西他滨(GEM)方案治疗老年晚期非小细胞肺癌(NSCLC)的疗效、不良反应和生存质量。方法对78例老年晚期NSCLC患者随机分组,实验组(45例)接受L-OHP加GEM方案治疗,对照组(33例)接受DDP加GEM方案治疗,观察并比较其疗效、不良反应和生存质量。结果近期疗效:实验组的有效率为(CR PR)37.8%,肿瘤控制率(临床受益率CR PR SD)为77.8%。对照组的有效率为39.4%,肿瘤控制率为69.7%。不良反应:血液学毒性实验组与对照组相似。周围神经毒性实验组比对照组发生率高,但无较严重运动神经损害且为可逆转。消化道反应实验组较对照组发生率有明显下降。生存质量:实验组比对照组有明显改善。结论对老年晚期NSCLC患者,L-OHP加GEM方案与DDP加GEM方案疗效相仿,但具有较为满意的疾病控制率,较低的消化道反应,生存质量有明显改善,是老年晚期NSCLC患者较为合适的一线治疗方案。

Comparative Study of Oxaliplatin Combined Chemotherapy Regimen and Cisplatin Combined Chemotherapy Regimen in Treatment of Advanced Non-small Cell Lung Cancer in Senile Patients

OBJECTIVE To compare the effect,adverse reaction and the quality of life between oxaliplatin(L-OHP) gemcitabine(GEM) regimen and cisplatin(DDP) gemcitabine(GEM) regimen in treatment of advanced non-small cell lung cancer(NSCLC) in senile patients.METHODS 78 cases NSCLC patinets were randomly divided into two groups.Study group(45 cases) received L-OHP GEM regimen,control group(33 cases) received DDP GEM regimen.The effect,untoranced reaction and the quality of life of two groups were observed and compared. RESULTS The recently response: the efficiency rate(CR PR) is 37.8%,the tumor control rate(CR PR SD) is 77.8% in study group,and the efficiency rate is 39.4%,the tumor control rate is 69.7% in control group.The adverse reaction: bone marrow suppression was similar between two groups.The incidence rate of peripheral neurotoxicity in study group was higher than control group,but without serious neurimotor injury and the ingury was reversible.The incidence rate of gastrointestinal reaction in study group was apparently decreased comparing with control group.The life quality of study group was apparently improved. CONCLUSION For senile patients,the efficiency of response was similar between L-OHP GEM regimen and DDP GEM regimen,and it was comparative satisfactory disease control rate,lower gastrointestinal reaction and apparently improved life quality for L-OHP GEM regimen,and it is a suitable first-line regimen for senile patients.